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ABSTRACT
A mathematical model is used to describe uptake
by a countertransport system and subsequent flow of
three amino acids (AA), Phe, Val, and Met, from
arterial blood to milk protein in the mammary gland
of a lactating cow. The model suggests that total
uptake of all AA is higher than net uptake and that a
large proportion of the incoming AA is released from
the cell directly back to blood. The model is used to
predict which of the three AA is limiting the rate of
milk protein synthesis and the response to increased
arterial concentration of the first-limiting AA. Simu-
lations are performed to predict possible outcomes of
several experimental protocols to AA infusion, which
might be used to test in vivo the responsiveness of the
bovine mammary gland to an altered arterial concen-
tration of AA. Of the three AA considered, arterial
Met concentration appears to be first-limiting. The
infusion profile that gives the greatest response in
milk protein synthesis rate alters the arterial profile
of AA such that it is identical to that of proteins
originating in the mammary gland. Model construc-
tion can be simplified by acknowledging normal bio-
logical constraints.
( Key words: amino acid, transport, uptake, inhibi-
tion)
Abbreviation key: MOP = mammary origin pro-
teins.
INTRODUCTION
The increased demand for protein from dairy
products has stimulated interest in the process of
protein synthesis in the lactating bovine mammary
gland and in understanding which factors limit the
rate of the overall process. Amino acids from arterial
blood are the precursors of milk proteins that are
synthesized in the mammary gland. Amino acid up-
take by cells (4) , including bovine mammary cells
(3) , is accomplished by a family of 13 different
membrane-bound AA transporters. The AA specificity
of these individual transporters varies widely; some
transport only specific AA, and others transport a
variety of AA. A complete understanding of AA up-
take by the gland would entail consideration of all
permutations involving greater than 20 amino acids
and 13 different transporters. Therefore, simpler
transport models are needed to advance understand-
ing and to determine whether AA transport limits
protein synthesis. The specificity of the AA transport-
ers supports the need to treat each AA as a specific
metabolite. However most previous modeling efforts
have simplified the process by treating AA as a
homogeneous group (2, 5, 10, 25).
Essential AA, which are used for milk protein syn-
thesis, have been divided into two discrete categories
(14); group I comprises AA that appear to be secreted
stoichiometrically in milk with their net uptake by
the mammary gland, and group II comprises AA that
are secreted in milk in quantities lower than those
taken up by the gland. It may be more than coinci-
dence that four of the five AA designated to group I
are transported primarily by the L system AA trans-
porter (3, 4). The unique characteristic of this trans-
porter is that it acts as a countertransporter and
exports one AA residue out of the cell for each AA
residue that it imports into the cell. The net rate of
influx into a cell or rate of efflux out of a cell of total
AA transported by this method is dependent on the
relative concentration gradients of AA, which are
transported by this system, on opposite sides of the
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Figure 1. Schematic representation of the model. Square with
double lines represents lactating mammary alveolar cell, squares
with single lines represent total AA pools, and arrows represent
fluxes of AA from one pool to another. Second letter of abbrevia-
tions indicate AA: M = Met, V = Val, and P = Phe.
membrane (3, 4). The rate of milk protein synthesis
may be limited by the net rate of uptake of these
essential AA, and, therefore, indirectly by the activity
level of the L system transporter.
A mechanistic dynamic two-pool mathematical
model of AA uptake by the lactating bovine mammary
gland is described and used to estimate total uptake
and net uptake of two group I AA, Phe and Met, and
one group II AA, Val, which are transported primarily
by the L system transporter. The model determines
whether competitive inhibition, that is, the reduction
in transport of one AA because of increased competi-
tion for limited transport capacity by another AA,
may be a factor in limiting AA uptake and, therefore,
in limiting the rate of milk protein synthesis. The
model simulates the potential effects of increasing
arterial concentrations of individual AA or specific
groups of AA, as would be done with close arterial
infusion of AA to the bovine mammary gland.
MATERIALS AND METHODS
Model Description
The model used is a modified version of a previ-
ously reported model (13) and represents the refer-
ence animal, a cow producing 30 L·d–1 of 3.34% total
protein milk (Figure 1). The model considers AA
utilization by the secreting alveolar cells producing
all mammary origin proteins ( MOP) found in bovine
milk, which include caseins, a-LA, and b-LG. The
cells have two intracellular pools containing either
free AA or AA that is bound in milk protein. Oxida-
tion and transamination of Met and Phe within the
gland is assumed to be negligible (11), and oxidation
of Val within the cell is set at 30% of net uptake (20).
Transamination of Phe to Tyr was disregarded be-
cause of the low activity of Phe hydroxylase in mam-
mary tissue of lactating ruminants when arterial Phe
concentrations were within the normal physiological
range (24).
The model is completely defined by Equations [A1]
to [A45] given in Appendix 1; the mathematical nota-
tion employed is given in Tables A1, A2, and A3. The
computer program used to solve the model was writ-
ten in Advanced Continuous Simulation Language
(1) , and a fourth-order, fixed-step Runge-Kutta al-
gorithm was used to integrate the differential equa-
tions numerically to predict pool sizes and the for-
ward and reverse flux rates of AA from each pool to
the next. The integration step length was made suffi-
ciently small so as not to introduce numerical insta-
bility by bridging any discontinuities (8) . The model
utilizes simple kinetic equations to represent forward
and reverse fluxes of AA from arterial blood through
two intermediate pools into secreted milk protein.
Energy-yielding substrates could also potentially
limit the rate of MOP synthesis but were not consi-
dered in this model.
Biological Constraints and Assumptions
The description of a complex system by means of a
model can be simplified substantially if known biolog-
ical constraints are applied. For example, the rate of
flux of individual AA relative to the rate of flux for
other AA from the intracellular pool of free AA of the
lactating cell into the intracellular pool of milk pro-
tein as protein translation occurs is stringently con-
strained because the AA profile of all MOP is fixed
(17). The corollary is that intracellular milk protein,
which subsequently undergoes hydrolysis within the
cell, supplies a fixed AA profile. The assumption is
made here that the L system transporter has equal
affinity for all three AA; therefore, the influx and
efflux of each AA are proportional to their individual
proportion of total AA concentration on that particu-
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TABLE 1. Secretion rate of Phe, Val, and Met in milk of a cow producing 1.25 L·h–1 of milk containing 3.34% protein.
1Composition of bovine milk protein (6) .
2Molecular mass of each individual protein component (23).
3Number of molecules per molecule of each respective protein (15).
Protein Protein
component Composition1 mass2 Protein Phe Val Met Phe Val Met
(% of total) (g·h–1) (mol·h–1) (no.)3 (mmol·h–1)
as1-CN 31.3 13.07 23,615 5.53 × 10–4 8 11 5 4.43 6.08 2.76
as2-CN 8.4 3.51 25,230 1.39 × 10–4 6 14 4 0.83 1.96 0.56
b-CN + g-CN 32.0 13.36 23,983 5.57 × 10–4 9 19 6 5.01 10.58 3.34
k-CN 10.5 4.38 19,025 2.30 × 10–4 4 11 2 0.92 2.53 0.46
b-LA 9.6 4.01 18,283 2.19 × 10–4 4 10 4 0.88 2.19 0.88
a-LG 3.8 1.59 14,176 1.12 × 10–4 4 6 1 0.45 0.67 0.11
Nonmammary 4.4 1.84
Total 100.0 41.75 12.52 24.01 8.10
lar side of the membrane. The total AA flux rate
varies with the total concentration of all AA.
The uptake of total AA is calculated using
Michaelis-Menten saturation kinetics (13) and the
sum of arterial blood concentrations of the individual
AA (Equation [A5]). Uptakes of each individual AA
(Phe, Val, and Met, respectively) from arterial blood
are then calculated as a proportion of the total flux
(Equations [A6], [A7], and [A8]), based on the propor-
tion of each individual AA in whole blood. The fluxes
of each AA into blood from the intracellular pool of
free AA are calculated similarly to total flux using the
total intracellular concentration of free AA (Equation
[A13]), which is then subdivided based on the propor-
tion of each of the three individual AA (Equations
[A14], [A15], and [A16]). Oxidation of Val is set at
30% of net Val uptake (Equation [A17]).
The output of each individual AA in MOP for the
reference animal model is calculated in Table 1. Us-
ing the AA profile of each of these proteins, a midlac-
tation cow producing 1.25 L·h–1 of milk with 3.34%
protein would secrete 12.52 mmol·h–1 of Phe, 24.01
mmol·h–1 of Val, and 8.10 mmol·h–1 of Met.
Table 2 shows the method of calculation of maxi-
mum rate values for the utilization of each individual
AA for MOP synthesis. The maximum rate of AA
utilization is dependent on many factors, including
the total number of lactating alveolar cells in a bovine
udder, which has been estimated to be approximately
1.0 × 1013 (16). The number of mRNA for casein,
which has previously been estimated to be approxi-
mately 1.0 × 105 cell–1 (9) , was increased for this
model to 1.2 × 105 cell–1 to account for whey protein
mRNA. The product of number of cells and number of
mRNA per cell gives a total of 1.2 × 1018 mRNA
molecules being translated for MOP simultaneously
in a complete bovine udder. The total number of
mRNA is subdivided into MOP component protein
mRNA by the relative proportions of each MOP found
in milk (Table 1). The structure of the model as-
sumes that the peptide elongation step is the limiting
step in protein translation. Estimates of maximal
initiation rate, which is suggested as being the limit-
ing step in prokaryotic cells (7,19), were not found
for ruminant tissues. Each molecule of mRNA can
have many ribosomes associated with it that simul-
taneously perform translation; however, these ribo-
somes must be a minimum number of mRNA codons
apart. The total number of active ribosomes is esti-
mated by dividing the total number of codons per
molecule of mRNA by 6, thus, assuming a minimum
separation of 6 codons (22). The product of the num-
ber of mRNA units and the number of ribosomes per
mRNA gives the total number of ribosomes that are
operating simultaneously. Estimates of the rate of AA
peptide bond formation by ribosomes range from 3 to
6 s–1 (21); therefore, a value of 4 s–1 was selected.
Thus, the total rate of AA incorporation into MOP is
the product of the number of active ribosomes and the
rate of peptide bond formation. The incorporation rate
of any single specific AA, however, would be equal to
its individual proportion of the total AA profile, for
example, 8 of 214 in the case of the simultaneous rate
of Phe incorporation into aS1-CN. Thus, the calcu-
lated maximum rate for the incorporation of Phe, Val,
and Met into milk protein is 37.44, 74.43, and 28.20
mmol·h–1, respectively, based on the proportion of
each individual MOP secreted. These values are used
as maximum rate values for fluxes (Table A3).
The overall rate of MOP translation in the model is
constrained by the intracellular concentration of the
first-limiting AA. A potential rate of utilization of
each individual AA, based on its intracellular free
concentration at that point in time, is calculated at
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TABLE 2. Calculation of maximum rate of utilization of Phe, Val, and Met for milk protein in the bovine mammary gland.
1Number of AA per molecule of translated protein (14).
2Number of individual ribosomes translating each protein.
3The AA composition of all proteins is the same as in Table 1 with additional requirements for the signal peptide (14).
Protein Total
component mRNA mRNA AA1 Rib2 Phe3 Val Met Phe Val Met
(% of total) (no.) (mmol·h–1)
as1-CN 31.3 3.92 × 1017 214 35.67 8 12 6 12.51 18.78 9.38
as2-CN 8.4 1.06 × 1017 222 37.00 9 15 6 3.79 6.31 2.52
b-CN + g-CN 32.0 4.01 × 1017 224 37.33 9 22 7 14.41 35.23 11.21
k-CN 10.5 1.32 × 1017 184 30.67 7 13 4 3.68 6.83 2.10
b-LG 9.6 1.20 × 1017 177 29.50 4 12 5 1.92 5.77 2.40
a-LA 3.8 4.76 × 1016 138 23.00 6 8 3 1.14 1.52 0.57
Total 1.20 × 1018 100.0 1.20 × 1018 37.44 74.43 28.20
each iteration of the model (Equations [A18], [A19],
and [A20]). A value is then calculated for the ratio of
potential utilization compared with the maximum
utilization rate (Equations [A21], [A22], and [A23]).
These values are sorted using a Fortran procedure,
and the lowest value is selected as being first-limiting
(Equations [A24], [A25], and [A26]). The MOP syn-
thesis proceeds at this rate, based on the sum of the
AA flux rates (Equations [A27], [A28], and [A29])
and on the proportion of each AA in MOP. Conversely,
the hydrolysis of intracellular milk protein and the
associated flux of AA from the intracellular pool of
milk protein into the intracellular pool of free AA are
calculated as 30% of the total MOP synthetic rate
(Equations [A36], [A39], and [A42]) (18).
Simulations Performed
Several experiments were simulated using the
model. Initially the model was allowed to achieve
steady state, thus, yielding predictions of normal flux
rates, pool sizes, and concentrations in the mammary
gland of the reference cow. Analyses were then per-
formed to determine which arterial AA concentration,
if any, was limiting the total MOP synthesis rate.
Subsequently, simulations were run to determine the
effects of competitive inhibition of AA uptake on all
flux rates and pool sizes by increasing the arterial
concentration of the AA that were not first-limiting
(Table 5). Next, the arterial concentration of the
first-limiting AA was increased in small increments
to determine the level at which it was no longer first-
limiting. Arterial concentrations were then increased
in a coordinated pattern to determine the maximum
rate of MOP synthesis.
A series of simulations were run using the model to
show the likely effects of various experimental infu-
sion protocols that might be used in vivo. Thus, the
model was used to test for the effects of arterial
infusion of AA as infusions of single AA or of various
AA mixtures on the rate of MOP synthesis. The quan-
tity of each AA that would be infused directly into the
arteries supplying the two sides of the bovine mam-
mary gland in an in vivo experiment was calculated
both in millimoles per hour and grams per hour and
is based on a blood flow ratio (liters) of mammary
blood flow to milk produced of 750:1 (12).
The purpose of this simulation study was to de-
velop a precise and robust method of identifying limit-
ing AA or kinetic parameters that were limiting the
rate of MOP synthesis. The choice of experimental
protocol used in vivo, such as the AA profile of the
infusion mixture, is important because several possi-
ble protocols are logical alternatives and merit con-
sideration. The model allows us to test various ex-
perimental protocols to obtain an understanding of
which ones would be most likely to yield useful
results from an in vivo experiment.
The experimental infusion protocols tested here
(Table 3) are compared with the reference cow and
include the following: P1, normal uninfused reference
cow; P2, infusion of three AA, on a molar basis, in a
mixture of the same profile found in MOP, which
would be similar to casein infusion and would be at
an infusion rate such that arterial concentration of
the first-limiting AA (Met) increased incrementally
by 10%; P3, as P2, but Met concentration increased
incrementally by 20%; P4, as P2, but Met concentra-
tion increased incrementally by 30%; P5, infusion of
an AA mixture to attempt to bring the arterial con-
centration of all three AA up to the level of the AA
that was initially the highest, Val at 3.71 × 10–4
mmol·ml–1; P6, if the original arterial concentration
of Val was the highest, and, concomitantly, first-
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TABLE 3. Arterial concentrations under various infusion protocols and infusion rates of individual AA.
Infusion
protocol
Arterial Infusion rate
Phe Val Met Phe Val Met
(mmol·ml) (mmol·h–1) (g·h–1) (mmol·h–1) (g·h–1) (mmol·h–1) (g·h–1)
P1 5.68 × 10–5 3.71 × 10–4 1.96 × 10–5 0 0 0 0 0 0
P2 5.94 × 10–5 3.76 × 10–4 2.16 × 10–5 2.4 0.40 4.7 0.55 1.9 0.03
P3 6.20 × 10–5 3.81 × 10–4 2.35 × 10–5 4.9 0.80 9.4 1.10 3.7 0.06
P4 6.46 × 10–5 3.86 × 10–4 2.55 × 10–5 7.3 1.21 14.1 1.65 5.5 0.10
P5 3.71 × 10–4 3.71 × 10–4 3.71 × 10–4 294.6 48.67 0 0 329.4 5.76
P6 4.08 × 10–4 4.08 × 10–4 4.08 × 10–4 329.3 54.40 34.7 4.07 364.1 6.37
P7 8.52 × 10–5 5.57 × 10–4 2.94 × 10–5 26.6 4.40 174.4 20.40 9.2 0.16
P8 1.14 × 10–4 7.42 × 10–4 3.92 × 10–5 53.6 8.86 347.8 40.80 18.4 0.22
P9 1.86 × 10–4 3.71 × 10–4 1.40 × 10–4 121.1 20.01 0 0 112.9 1.97
TABLE 4. Arterial concentrations of AA and concentrations of free
AA in the intracellular pool and the ratio of intracellular to arterial
concentration as predicted by the model.
Concentration
AA Arterial Intracellular Ratio
(mmol·ml–1)
Phe 5.68 × 10–5 5.60 × 10–4 10
Val 3.71 × 10–4 4.50 × 10–3 12
Met 1.96 × 10–5 9.77 × 10–5 5
Total 4.47 × 10–4 5.16 × 10–3 12
limiting, protocol P5 would have no effect; therefore,
another protocol in which the arterial concentration of
all three would be increased to the level of the initial
highest increased by 10% (i.e., all would be increased
to 4.08 × 10–4 mmol·ml–1) ; P7, increase the respective
arterial concentration of all three AA by 50%; P8,
increase of all arterial concentrations 100%; P9, infu-
sion to achieve arterial concentrations of the same
ratio as that required for MOP translation Phe:Val:
Met of 1.33:2.64:1.00, respectively. Table 3 presents
the target arterial concentration for each of the AA
and the required infusion rate, in millimoles per hour
or grams per hour to produce this concentration. Total
infused quantities range from 9 to 728 mmol·h–1,
which is reasonable for infusion experiments with
lactating dairy cows.
RESULTS AND DISCUSSION
This study demonstrates how mathematical model-
ing can aid the design of animal experiments and, in
this case, provide guidance as to the quantities and
profiles of AA to be used in AA infusion experiments.
Using this simple mechanistic model, several key
principles emerged regarding the biological limita-
tions or the current understanding of the biological
limitations of this complex process. The L system
transporter has been shown to be independent of Na+
(4) . The rate of flux of all AA that pass through this
transporter is controlled by the concentration of AA
on both sides of the membrane. In the model the
starting values for concentrations of free AA in the
intracellular pool were set at the same values as
those of whole blood. Dynamic models, such as this
one with a small integration interval, reach
equilibrium rapidly so that initial starting values are
not of great consequence. When the three AA were
considered as a homogeneous pool, the intracellular
AA concentration that was predicted by the model for
the reference cow model was 12-fold higher than that
of whole blood (Table 4). The AA transporters
usually exhibit concentrative uptake against a con-
centration gradient; however, the magnitude of the
increased intracellular concentration that is predicted
by the model was higher than expected. When consi-
dered individually, the intracellular concentrations of
Phe, Val, and Met are 10-, 12-, and 5-fold higher than
those of whole blood, respectively; the values of in-
dividual AA concentrations could not be predicted by
the concentration of total AA only, which highlights
two important points. Treatment of the total pool of
AA as a single homogenous pool might not be an
appropriate simplification and could lead to a mis-
understanding of the biological processes. Also, be-
cause of the constraints imposed on AA transport and
protein translation, the intracellular pool of free AA
must act as a buffer between these two highly con-
strained systems, thus, allowing these relatively in-
flexible systems to continue to operate at acceptable
efficiency.
Model results predict a profile of free AA in the
intracellular pool that is different from that of whole
blood or of synthesized protein (Figure 2) being re-
quired to support MOP synthesis. If the L system
transporter has equal binding affinity for each of the
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Figure 2. Profiles of AA in blood and milk and model predictions
of the free AA in the intracellular pool relative to Met concentra-
tion.
TABLE 5. Effect of increasing arterial concentrations of AA on
synthesis rate of proteins of mammary origin.
Increase Protein
synthesis
ratePhe Val Met
( % ) (g·h–1)
0 0 0 41.75
10 10 0 41.29
20 20 0 40.84
30 30 0 40.39
0 0 50 54.51
0 0 100 62.83
0 0 150 68.24
0 0 200 68.58
0 0 250 68.52
10 0 200 70.70
20 0 200 71.84
30 0 200 71.82
30 0 250 73.84
AA that it transports, the system is tightly con-
strained. The different AA profile of the intracellular
pool compared with that of blood is an indication that
the profile of AA being exported to blood is different
from the profile of AA being taken up from blood or
being removed from the intracellular free pool for
protein synthesis. When all AA are considered, along
with AA oxidation and transamination, the ideal AA
profile of arterial blood to support maximum protein
synthesis rate may be quite different from that of
MOP.
In such a constrained system, provision of an ade-
quate supply of the first-limiting AA appears to be
accomplished by a relatively high influx and efflux of
all AA involved. The profile of AA in the influx or
efflux changes little over time, and an increased total
flux in both directions eventually leads to a difference
in total net uptake that is adequate to support protein
synthesis. At first, this system appears to be ineffi-
cient at removing AA from blood, but the L system
transporter may conceivably be the best method that
has evolved to handle AA with large side chains, such
as the large branched or aromatic side-chain struc-
tures found in Phe, Tyr, Trp, Val, Ile, and Leu. This
analysis also shows that, to understand the system
completely, the experimenter must be familiar with
flux quantities in absolute amounts, such as milli-
moles per day and as ratios of AA. In addition, an
analysis that is totally dependent on one or the other
alone can be quite misleading.
An increase in arterial concentrations of Phe and
Val in 10% increments had minimal effects on the
rate of MOP synthesis (Table 5). Competitive inhibi-
tion of uptake could limit MOP synthesis rate;
however, a 30% increase in the arterial concentration
of two AA that compete for transport capacity, but are
not limiting, resulted in only a 3.6% decrease in MOP
synthesis rate. One might expect that an increase in
the arterial concentration of any AA transported by
the L system transporter might increase the total
transport rate and, therefore, might concomitantly
increase the supply of the first-limiting AA; however,
the model suggests that this scenario is incorrect.
Incremental increases in the arterial concentration
of Met increased rate of MOP synthesis (Table 5),
suggesting that, among the three AA discussed here,
Met is most likely first-limiting. Increases in arterial
concentrations of Met were associated with nonlinear
(diminishing returns) increases in the rate of MOP
synthesis up to the point at which Met was increased
by 200%. An increase in arterial concentrations of
Met above 200% slightly decreased the synthesis rate
because of competitive inhibition and because Phe
had become first-limiting. Maintenance of Met at the
200% increase level, as the arterial concentration of
Phe increased, further increased the rate of MOP syn-
thesis. This pattern continued until the arterial con-
centration of Phe had been increased by 30%; then,
subsequent increases slightly reduced the overall syn-
thesis rate. The model demonstrates clearly that
small increases in the supply of the first-limiting AA
Journal of Dairy Science Vol. 81, No. 6, 1998
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TABLE 6. Flux rates between pools predicted by model under various infusion protocols.
1FIPBP = Phe flux from arterial blood free pool to intracellular free pool, FIVBV = Val flux from
arterial blood free pool to intracellular free pool, FIMBM = Met flux from arterial blood free pool to
intracellular free pool, FBPIP = Phe flux from intracellular free pool to arterial blood free pool, FBVIV =
Val flux from intracellular free pool to arterial blood free pool, and FBMIM = Met flux from intracellular
free pool to arterial blood free pool.
Infusion protocol
Flux1 P1 P2 P3 P4 P5 P6 P7 P8 P9
(mmol·h–1)
Total AA influx 334.1 339.6 344.9 350.3 616.1 649.5 448.7 541.4 460.3
Total AA efflux 276.7 278.1 279.9 281.7 500.9 532.7 376.6 459.4 348.0
Uptake
efficiency, % 17.2 18.1 18.9 19.6 18.8 17.9 16.1 15.2 24.4
Uptake
Phe FIPBP 42.4 44.1 45.8 47.5 205.4 216.5 56.9 68.9 122.8
Val FIVBV 277.1 279.4 281.7 284.0 205.4 216.5 372.2 448.7 245.0
Met FIMBM 14.6 16.1 17.4 18.8 205.4 216.5 19.6 23.7 92.4
Output
Phe FBPIP 29.9 30.7 31.7 32.6 180.0 191.1 41.2 51.1 98.4
Val FBVIV 241.5 241.4 241.5 241.6 133.4 144.3 327.6 398.0 175.6
Met FBMIM 5.2 6.0 6.7 7.5 186.3 197.3 7.8 10.3 74.0
TABLE 7. Amino acid pool sizes predicted by model under various infusion protocols.
Infusion protocol
Pool P1 P2 P3 P4 P5 P6 P7 P8 P9
(mmol)
Total intracellular AA 56.74 57.09 57.55 58.03 127.22 140.64 84.60 112.06 76.10
Intracellular pool
Phe 6.13 6.31 6.51 6.72 45.83 50.44 9.26 12.46 21.51
Val 49.54 49.56 49.66 49.77 33.96 38.09 73.58 97.09 38.39
Met 1.07 1.22 1.38 1.55 47.43 52.10 1.75 2.50 16.19
Rate of MOP synthesis,
g·h–1 41.75 44.70 47.29 49.81 84.55 84.86 52.44 59.58 81.56
could potentially allow dramatic increases in the over-
all rate of MOP synthesis and that eventually this
limitation is overcome. Subsequently, the largest
overall response comes from supplying the correct
profile of all AA.
Several research groups have expended considera-
ble effort to produce an in vivo animal preparation by
which arterial concentrations of the AA supplying the
lactating mammary gland can be manipulated via
arterial infusion. The model suggests that all AA flux
rates within the gland would respond to altered ar-
terial AA concentrations (Table 6) using the ex-
perimental infusion protocols discussed previously
(Table 3). Pool sizes and pool size ratios of individual
AA pools, in response to each of the infusion protocols,
are shown in Tables 7 and 8, respectively.
The first three infusion protocols, P2 to P4, in
which the infusate contains AA in the same propor-
tions as found in MOP, allow an increased rate of
MOP synthesis. An effect of the infusion of this AA
profile is that the size of the intracellular pool of Met
increases proportionally much more than that of the
other AA (Table 7). Over the entire range of increase
in arterial concentration of these three AA, the size of
the intracellular pool of Val increases 1%, of Phe
increases 9%, but of Met increases 50%. The increase
in the total rate of AA uptake rate by the cells is
greater than the increase in AA efflux into blood
(Table 6); therefore, most of the increased Met up-
take is going directly to MOP.
Infusion protocols P5 and P6 produce the greatest
increase in the rate of MOP synthesis, which is not
surprising considering that those protocols also re-
quire the highest infusion rates (Table 3) and result
in the least efficient net uptake (Table 6), which is
measured as the proportion of the AA uptake that
goes directly to MOP synthesis. The higher infusion
rate in protocol P6 than in P5 resulted in a small
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TABLE 8. Ratio of AA (Phe:Val:Met) in blood and intracellular
pools of free AA under various infusion protocols.1
1The ratio of AA in mammary origin proteins is constant at 1.3:
2.6:1.0.
Protocol Blood Intracellular pool
P1 2.9:18.9:1.0 5.7:46.3:1.0
P2 2.9:17.4:1.0 5.2:40.6:1.0
P3 2.6:16.2:1.0 4.7:36.0:1.0
P4 2.5:15.1:1.0 4.3:32.1:1.0
P5 1.0:1.0:1.0 1.0:0.7:1.0
P6 1.0:1.0:1.0 1.0:0.7:1.0
P7 1.3:19.0:1.0 5.3:42.4:1.0
P8 2.9:189.0:1.0 5.0:38.8:1.0
P9 1.2:2.7:1.0 1.3:2.7:1.0
increase in MOP synthesis rate. This increase is
reasonable considering that the arterial level of all
AA was increased to that of the AA that was initially
the highest. In this case, that AA was not the first-
limiting AA, and, therefore, protocol P5 overcomes the
limitation. Importantly, the amount of AA that was
infused to accomplish these protocols was of suffi-
ciently small quantity to allow the procedure to be
performed in vivo. Although not tested directly, these
results suggest that high levels of infusion, particu-
larly with a solution of inappropriate AA profile, with
a goal of saturating one part of the system, may cause
nonphysiological results and, thus, lead to false con-
clusions. Infusion rates must be considered carefully
to produce arterial concentrations that are within a
realistic physiological range so that useful results are
obtained.
Protocols P7 and P8, which increased the arterial
concentration of all three AA by 50 and 100% of the
original value, allowed substantial increases in the
rate of MOP synthesis. However, these results must
be viewed with caution because the primary cause of
the increased synthesis rate is the increased supply of
the first-limiting AA. The increased supplies of Phe
and Val have minimal effect on the rate of MOP
synthesis. Increasing arterial Met concentration by 50
or 100% gave MOP synthesis rates of 54.25 and 61.72
g·h–1, respectively, which were slightly higher than
the increases when all AA were increased simultane-
ously. Again, this result demonstrates how ex-
perimental results could be misinterpreted when ac-
quired from infusion experiments using an in vivo
preparation.
The final protocol tested was P9; arterial concen-
trations were altered such that the resulting arterial
concentrations of AA were the same profile as that of
MOP. Protocol P9 was the most efficient in terms of
AA capture in MOP as a proportion of the total taken
up by the lactating cells. Net uptake efficiency was
also the highest of all the infusion protocols, yet still
appeared low at approximately 24.4%. Infusion rates
for this protocol were intermediate between the
lowest and highest used in other protocols discussed,
yet the predicted rate of MOP synthesis is very close
to the maximum achieved with any of the infusion
mixtures. These results suggest that the ideal AA
pattern in arterial blood is similar to that of the
profile in MOP and that careful calculation is needed
to ensure infusions that attain this profile. The resul-
tant profile for arterial AA in this protocol is quite
different from the one achieved by infusion of a solu-
tion that contains the same profile as MOP.
CONCLUSIONS
This theoretical model provides useful insight into
the limitations of MOP synthesis in the lactating
bovine mammary gland. The model provides guidance
in the selection of quantities and profiles of AA for
infusion that merit experimental testing and suggests
that some AA are of little value. Experiments that
infuse high levels of AA or inappropriate AA profiles
could lead to very small responses in MOP synthesis
rate and to incorrect conclusions from experimental
results. Experimentally imposed perturbations to the
system must be within physiological limits in order to
obtain useful results.
Results from simulated infusion protocols that
were associated with increased MOP synthesis rate
suggested that the profile of AA in the intracellular
pool of free AA also changed. The proportion of the
intracellular pool of free AA that was occupied by the
first-limiting AA (Met in this case) increased sub-
stantially as the rate of MOP synthesis increased.
The concentrations of individual AA in this pool do
not increase in the same proportion as the increase in
blood. Therefore, the model suggests that considera-
tion of all AA as a single homogeneous pool may be an
inappropriate simplification that could lead to errone-
ous conclusions.
The optimal efficiency of AA uptake that was
predicted by the model indicated that only 24.4% of
AA extracted from blood was directed toward MOP
synthesis. However, this proportion could be quite
efficient in biological terms, and, therefore, ex-
perimenters need to keep an open mind about what
constitutes a realistic range, particularly in an area
such as this, for which only minimal experimental
data exist. As suggested earlier, this result is perhaps
the most efficient system available for transporting
bulky AA.
The model predicts that the profile of arterial AA
supporting a maximum rate of MOP synthesis, is the
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same AA profile as MOP. This result may be some-
what limited by the use of a simplified model and
may be quite different when all AA are considered,
particularly AA that appear to be used primarily for
oxidation. The values predicted by the model would
obviously be of much greater utility if comparison
could be made with actual in vivo experimental data.
The overall process of MOP synthesis is complex,
and reducing the process to its component parts facili-
tates understanding. This model suggests that the
overall process may not be highly regulated but,
rather, may be very highly restricted by several bio-
logical constraints. This distinction is subtle, yet very
important, when attempting to find methods of
manipulating the MOP synthesis system in the lac-
tating cow. The model also demonstrates how systems
that are inflexible, such as that of AA uptake and
MOP translation, can be buffered by the intracellular
pool of free AA.
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APPENDIX 1
Pool Dynamics: Input and Output
Equations
Total AA concentration in arterial blood (TBA) :
Concentration: TBA = CBP + CBV + CBM. [A1]
Proportion of each AA in blood (PBP, PBV, and PBM):
Phe: PBP = CBP/TBA. [A2]
Val: PBV = CBV/TBA. [A3]
Met: PBM = CBM/TBA. [A4]
Journal of Dairy Science Vol. 81, No. 6, 1998
MODEL OF COMPETITIVE INHIBITION OF AMINO ACID UPTAKE 1733
Total uptake of AA by cells from arterial blood
(FIABA) :
FIABA = VIABA/(1 + (KIABA/TBA) ) . [A5]
Uptake of individual AA by cells from arterial
blood (FIPBP, FIVBV, and FIMBM):
Phe: FIPBP = FIABAPBP. [A6]
Val: FIVBV = FIABAPBV. [A7]
Met: FIMBM = FIABAPBM. [A8]
Total concentration of free AA in the intracellular
pool (TIA) :
TIA = CIP + CIV + CIM. [A9]
Proportion of each free AA in the intracellular pool
(PIP, PIV, and PIM) :
Phe: PIP = CIP/TIA. [A10]
Val: PIV = CIV/TIA. [A11]
Met: PIM = CIM/TIA. [A12]
Total output of AA to arterial blood from cells
(FBAIA) :
FBAIA = VBAIA/(1 + (KBAIA/TIA) ) . [A13]
Output of individual AA to arterial blood from cells
(FBPIP, BBVIV, FBMIM, and FOVIV) :
Phe: FBPIP = FBAIAPIP. [A14]
Val: FBVIV = FBAIAPIV. [A15]
Met: FBMIM = FBAIAPIM. [A16]
Oxidation of Val: FOVIV = (FIVBV – FBVIV) × KOVIV.
[A17]
Theoretical maximum rate of incorporation of in-
dividual AA into milk protein (MAXFMPIP,
MAXFMVIV, and MAXFMMIM):
Phe: MAXFMPIP = VMPIP/(1 + (KMPIP/CIP) ) .
[A18]
Val: MAXFMVIV = VMVIV/(1 + (KMVIV/CIV) ) .
[A19]
Met: MAXFMMIM = VMMIM/(1 + (KMMIM/CIM) ) .
[A20]
Ratio of rate of incorporation to maximum rate of
incorporation into milk protein for each individual
AA:
Phe: RMP = MAXFMPIP/VMPIP. [A21]
Val: RMV = MAXFMVIV/VMVIV. [A22]
Phe: RMM = MAXFMMIM/VMMIM. [A23]
Procedure to determine which concentration of AA in
the intracellular pool is limiting the maximum rate of
milk protein synthesis (MAXMSYN):
Set first value: MAXMSYN = RMP. [A24]
Test against next: if RMV < MAXMSYN,
then MAXMSYN = RMV. [A25]
Test against next: if RMM < MAXMSYN,
then MAXMSYN = RMM. [A26]
Calculate the actual flux of each individual free AA
from the intracellular pool to intracellular milk pro-
tein (FMPIP, FMVIV, and FMMIM):
Phe: FMPIP = VMPIP × MAXMSYN. [A27]
Val: FMVIV = VMVIV × MAXMSYN. [A28]
Met: FMMIM = VMMIM × MAXMSYN. [A29]
Free Phe in the intracellular pool (IP):
Concentration: CIP = QIP/Wa. [A30]
Inputs: FIPBP Equation [A6];
FIPMP Equation [A36].
Outputs: FBPIP Equation [A14];
FMPIP Equation [A27].
Differential
equation:
dQIP/dt = FIPBP + FIPMP
– FBPIP – FMPIP.
[A31]
Free Val in the intracellular pool (IV):
Concentration: CIV = QIV/Wa. [A32]
Inputs: FIVBV Equation [A7];
FIVMV Equation [A39].
Outputs: FBVIV Equation [A15];
FMVIV Equation [A28];
FOVIV Equation [A17].
Differential
equation:
dQIV/dt = FIVBV + FIVMV
– FBVIV – FMVIV
– FOVIV. [A33]
Free Met in the intracellular pool (IM):
Concentration: CIM = QIM/Wa. [A34]
Inputs: FIMBM Equation [A8];
FIMMM Equation [A42].
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TABLE A1. Symbols for entities represented in the model.
Symbol Definition
BP Free Phe in blood
BV Free Val in blood
BM Free Met in blood
BA Total free AA in blood (BP + BV + BP)
IP Free Phe in the intracellular pool
IV Free Val in the intracellular pool
IM Free Met in the intracellular pool
IA Total free AA (IP + IV + IP)
MP Phe bound to milk protein in the intracel-
lular pool
MV Val bound to milk protein in the intracel-
lular pool
MM Met bound to milk protein in the intracel-
lular pool
OV Oxidation of Val within cell
SP Secreted Phe bound to milk protein
SV Secreted Val bound to milk protein
SM Secreted Met bound to milk protein
MAXF Theoretical maximum flux from free AA
in the intracellular pool to AA bound to
milk protein for each individual AA
MAXM Theoretical maximum rate of milk protein
synthesis acknowledging first-limiting AA
PDEG Degradation of intracellular milk protein
TABLE A2. Notation.
1The subscripts i, j, and k take values from Table A1.
Notation1 Definition Units
Ci Concentration of i millimoles per milliliter
Fjk Flux rate of j ← k
transaction
millimoles per hour
kjk Mass action constant for
j ← k transaction
per hour
Kjk Michaelis-Menten cons-
tant for j ← k trans-
action
millimoles per milliliter
Qi Quantity of i millimoles
Vjk Maximum rate for
j ← k transaction
millimoles per hour
Wa Mammary cell water
volume
milliliters
TABLE A3. Kinetic parameters.
1See Table A2 for units.
Parameter1 Value
CBP 5.68 × 10–5
CBV 3.71 × 10–4
CBM 1.96 × 10–5
VIABA 1.4235 × 103
KIABA 1.459 × 10–3
VBAIA 1.4235 × 103
KBAIA 2.148 × 10–2
VMPIP 37.44
KMPIP 1.07 × 10–4
VMVIV 74.43
KMVIV 1.07 × 10–4
VMMIM 28.20
KMMIM 1.07 × 10–4
KOVIV 0.30
KPDEG 0.30
Wa 1.095 × 104
Outputs: FBMIM Equation [A16];
FMMIM Equation [A29].
Differential
equation:
dQIM/dt = FIMBM + FIMMM
– FBMIM – FMMIM.
[A35]
Phe in intracellular milk protein (MP):
Inputs: FMPIP Equation [A27].
Outputs FIPMP = FMPIP × kPDEG; [A36]
FSPMP = FMPIP – FIPMP. [A37]
Differential
equation:
dQMP/dt = FMPIP – FIPMP
– FSPMP. [A38]
Val in intracellular milk protein (MV):
Inputs: FMVIV Equation [A28].
Outputs: FIVMV = FMVIV × kPDEG; [A39]
FSVMV = FMVIV – FIVMV.[A40]
Differential
equation:
dQMV/dt = FMVIV – FIVMV
– FSVMV. [A41]
Met in intracellular milk protein (MM):
Inputs: FMMIM Equation [A29].
Outputs: FIMMM = FMMIM × kPDEG;
[A42]
FSMMM = FMMIM – FIMMM.
[A43]
Differential
equation:
dQMM/dt = FMMIM – FIMMM
– FSMMM. [A44]
Secreted milk protein (SP):
Inputs: FSPMP.
Differential
equation: dQSP/dt = FSPMP. [A45]
